Erhan Capkin, Ali Yazıcı, Murat Karkucak, Yunus Durmaz, Murat Toprak, Şebnem Ataman, Nilay Şahin, Nihan Cüzdan, Meliha Kasapoğlu Aksoy, Mustafa Erkut Önder, Münevver Serdaroglu Beyazal, Nilgün Mesci, Merve Baykul, Meltem Alkan Melikoğlu, Hakan Alkan, Deniz Dulgeroglu, Ahmet Kıvanç Cengiz, Kemal Nas, Elif Balevi Batur, Aslı Çalışkan Uçkun, Hülya Deveci, Kemal Erol, İlknur Albayrak Gezer, Gürkan Akgöl, Mehmet Tuncay Duruöz, Okan Küçükakkaş, Selda Sarıkaya, Aylin Rezvani, Tuğba Atan, Feride Göğüş, Gökhan Çağlayan, Yaşar Keskin, Ayşe Selcen Bulut Keskin, Nuran Öz, Gürdal Yılmaz
To evaluate of hepatitis serology and reactivation frequency in patients with rheumatic disease receiving biologic agents. Our study included patients with inflammatory rheumatic diseases from 23 centers, who were followed up with biological therapy. Demographic and clinical characteristics of the patients, duration of drug use and hepatitis serology and the state of viral reactivation were analyzed. A total of 4060 patients, 2095 being males, were included in our study. Of the patients, 2463 had Ankylosing Spondylitis (AS), 1154 had Rheumatoid Arthritis (RA), 325 had Psoriatic Arthritis (PsA), and 118 had other inflammatory rheumatic diseases...
September 5, 2022: Rheumatology International